Skip to content

A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523108-59-00
Enrollment
136
Registered
2026-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe infections caused by Gram-negative bacteria

Interventions

None listed

Sponsors

Basilea Pharmaceutica International AG Allschwil
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 7, 2026